Nephros Inc Total Liabilities
Nephros Inc total liabilities. Based on the latest financial reports, Nephros Inc (NEPH) has total liabilities worth $3.09 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Nephros Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Nephros Inc (2001–2025)
Total liabilities of Nephros Inc from 2001 to 2025. This chart illustrates how Nephros Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Nephros Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Nephros Inc Competitors by Total Liabilities
The table below lists competitors of Nephros Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wisr Ltd
AU:WZR
|
Australia | AU$976.80 Million |
|
Atlanta Poland SA
WAR:ATP
|
Poland | zł104.82 Million |
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
USA | $66.80 Million |
|
Pancontinental Energy NL
AU:PCL
|
Australia | AU$580.18K |
|
TJ media Co. Ltd
KQ:032540
|
Korea | ₩43.56 Billion |
|
Mind Technology Inc
NASDAQ:MIND
|
USA | $7.40 Million |
|
YM Tech Co. Ltd.
KQ:273640
|
Korea | ₩4.19 Billion |
|
NuriFlex Co.Ltd
KQ:040160
|
Korea | ₩84.14 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Nephros Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Nephros Inc.
Liquidity & Leverage Metrics
Nephros Inc Total Liabilities Ratios Explained
Nephros Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nephros Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nephros Inc (2001–2025)
The table below shows the annual total liabilities of Nephros Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.44 Million | +31.01% |
| 2024-12-31 | $2.62 Million | -25.06% |
| 2023-12-31 | $3.50 Million | +65.39% |
| 2022-12-31 | $2.12 Million | -26.99% |
| 2021-12-31 | $2.90 Million | -1.23% |
| 2020-12-31 | $2.94 Million | -25.46% |
| 2019-12-31 | $3.94 Million | +4.79% |
| 2018-12-31 | $3.76 Million | +23.97% |
| 2017-12-31 | $3.03 Million | +50.82% |
| 2016-12-31 | $2.01 Million | +53.98% |
| 2015-12-31 | $1.31 Million | -85.57% |
| 2014-12-31 | $9.05 Million | +158.65% |
| 2013-12-31 | $3.50 Million | -15.13% |
| 2012-12-31 | $4.12 Million | +60.24% |
| 2011-12-31 | $2.57 Million | +76.84% |
| 2010-12-31 | $1.46 Million | +109.65% |
| 2009-12-31 | $694.00K | -53.79% |
| 2008-12-31 | $1.50 Million | +13.02% |
| 2007-12-31 | $1.33 Million | -81.70% |
| 2006-12-31 | $7.26 Million | +197.04% |
| 2005-12-31 | $2.45 Million | -4.36% |
| 2004-12-31 | $2.56 Million | -75.46% |
| 2003-12-31 | $10.42 Million | +12.31% |
| 2002-12-31 | $9.27 Million | +355.32% |
| 2001-12-31 | $2.04 Million | -- |
About Nephros Inc
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella a… Read more